Sign In
Buy CERU
$0.660
+0 (+0%)
At Close: Jan 16, 2018
Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23
09:38pm, Monday, 20'th Mar 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive shar
Cerulean to Host Third Quarter 2016 Conference Call on November 3
07:00am, Thursday, 27'th Oct 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate a
Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin® Combination in Relapsed Renal Cell Carcinoma
04:01pm, Wednesday, 17'th Aug 2016
WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced top-line results from the Company’s Phas
Cerulean to Host Second Quarter 2016 Conference Call on August 4
07:00am, Thursday, 28'th Jul 2016
WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate act
Cerulean to Host First Quarter 2016 Conference Call on May 2
07:00am, Monday, 25'th Apr 2016
WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate act
Cerulean to Host Fourth Quarter 2015 Conference Call on March 10
07:00am, Thursday, 03'rd Mar 2016
WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate act
Cerulean to Host Third Quarter 2015 Conference Call on November 16
07:00am, Thursday, 05'th Nov 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate a
Cerulean to Host Second Quarter 2015 Conference Call on August 6
07:00am, Thursday, 30'th Jul 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor TargetingTM, today announced it will provide an update on corporate activities for the second quarter
Cerulean to Host First-Quarter 2015 Conference Call on May 6
07:02am, Wednesday, 29'th Apr 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced it will provide an update on corporate activities for the first-quarter
Cerulean to Host Fourth-Quarter and Year-End 2014 Conference Call on March 19
07:30am, Thursday, 12'th Mar 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced it will provide an update on corporate activities for the fourth quarter
